Selecta Biosciences Stock Forecast, Price & News

-0.10 (-2.34 %)
(As of 09/16/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,770 shs
Average Volume1.34 million shs
Market Capitalization$479.88 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Selecta Biosciences logo

About Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.36 out of 5 stars

Medical Sector

204th out of 1,352 stocks

Pharmaceutical Preparations Industry

94th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

Is Selecta Biosciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Selecta Biosciences?

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Selecta Biosciences

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings data on Wednesday, August, 11th. The company reported $0.04 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.16. The company had revenue of $19.66 million for the quarter, compared to analysts' expectations of $10.83 million.
View Selecta Biosciences' earnings history

How has Selecta Biosciences' stock been impacted by Coronavirus (COVID-19)?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SELB shares have increased by 34.3% and is now trading at $4.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SELB?

7 Wall Street analysts have issued 12-month price targets for Selecta Biosciences' stock. Their forecasts range from $3.50 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $8.10 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price.
View analysts' price targets for Selecta Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:
  • Carsten Brunn, President, Chief Executive Officer & Director
  • Lloyd Johnston, COO, Senior Vice President-Research & Development
  • Ann K. Donohue, VP, Chief Financial & Accounting Officer
  • Takashi Kei Kishimoto, Chief Scientific Officer
  • Peter G. Traber, Chief Medical Officer

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering (IPO) on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.91%), Vanguard Group Inc. (4.45%), Nuveen Asset Management LLC (1.90%), Marshall Wace North America L.P. (1.78%), JPMorgan Chase & Co. (1.63%) and BVF Inc. IL (1.50%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Lloyd P Johnston, Peter G Traber, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., BVF Inc. IL, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, Citigroup Inc., Northern Trust Corp, and Susquehanna International Group LLP. Company insiders that have sold Selecta Biosciences company stock in the last year include Carsten Brunn, and Lloyd P Johnston.
View insider buying and selling activity for Selecta Biosciences
or view top insider-selling stocks.

Which major investors are buying Selecta Biosciences stock?

SELB stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BlackRock Inc., Bank of Montreal Can, Marshall Wace LLP, Marshall Wace LLP, Nuveen Asset Management LLC, JPMorgan Chase & Co., and Geode Capital Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences
or or view top insider-buying stocks.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $4.15.

How much money does Selecta Biosciences make?

Selecta Biosciences has a market capitalization of $477.58 million and generates $16.60 million in revenue each year. The company earns $-68,880,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Selecta Biosciences have?

Selecta Biosciences employs 44 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is

Where are Selecta Biosciences' headquarters?

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at (617) 923-1400 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.